- Home
- HROW vs REAL Comparison
HROW vs REAL Comparison
Compare HROW & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- REAL
- Stock Information
- Founded
- HROW 1998
- REAL 2011
- Country
- HROW United States
- REAL United States
- Employees
- HROW N/A
- REAL N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- REAL Other Specialty Stores
- Sector
- HROW Health Care
- REAL Consumer Discretionary
- Exchange
- HROW Nasdaq
- REAL Nasdaq
- Market Cap
- HROW 1.4B
- REAL 1.2B
- IPO Year
- HROW N/A
- REAL 2019
- Fundamental
- Price
- HROW $36.81
- REAL $12.45
- Analyst Decision
- HROW Strong Buy
- REAL Strong Buy
- Analyst Count
- HROW 7
- REAL 5
- Target Price
- HROW $68.50
- REAL $12.20
- AVG Volume (30 Days)
- HROW 804.0K
- REAL 3.1M
- Earning Date
- HROW 11-10-2025
- REAL 11-10-2025
- Dividend Yield
- HROW N/A
- REAL N/A
- EPS Growth
- HROW N/A
- REAL N/A
- EPS
- HROW N/A
- REAL N/A
- Revenue
- HROW $227,661,000.00
- REAL $636,971,000.00
- Revenue This Year
- HROW $43.92
- REAL $14.56
- Revenue Next Year
- HROW $41.22
- REAL $10.14
- P/E Ratio
- HROW N/A
- REAL N/A
- Revenue Growth
- HROW 47.69
- REAL 12.68
- 52 Week Low
- HROW $20.85
- REAL $2.81
- 52 Week High
- HROW $54.19
- REAL $12.81
- Technical
- Relative Strength Index (RSI)
- HROW 38.13
- REAL 67.04
- Support Level
- HROW $36.20
- REAL $12.11
- Resistance Level
- HROW $39.77
- REAL $12.81
- Average True Range (ATR)
- HROW 1.89
- REAL 0.61
- MACD
- HROW -0.40
- REAL 0.09
- Stochastic Oscillator
- HROW 9.98
- REAL 87.64
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.